China

Aspen China has delivered double-digit revenue growth year-on-year since it was established in FY2017. Our portfolio is led by our Thrombosis and Anaesthetics Brands and also comprises some smaller global brands. Our product portfolio is well placed to deliver value to Chinese patients given our focus on high quality, stable supply and affordable medicines with strong brand equity.

Contribution to Group revenue

Revenue contribution - by therapeutic category

The China pharmaceutical sector was valued at USD92 billion as at 31 December 2018 and grew 6%versus the prior comparable period

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: Nil)

Number of product recalls:

Nil

(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

USD16 million

Average staff turnover:

30,3%

(2018: 25,9%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

Revenue	2019 R'million	2018 (CER) R'million	change %
Total	2 872	2 544	13
Regional Brands	27	21	29
Sterile Focus Brands	2 845	2 523	13
Anaesthetics Brands	1 976	1 874	5
Thrombosis Brands	869	649	34

^{Note: Commercial Pharmaceuticals revenue is disclosed by customer geography.}